VITASPRING BIOMEDICAL CO (VSBC) Financials
Newest figures come from the 10-Q for Q1 FY2027, filed Jun 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VSBC SEC filings page.
VITASPRING BIOMEDICAL CO (VSBC) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Negative cash conversion and a receivables-heavy balance sheet made working capital the dominant business mechanic in FY2022.
Net income of$910K coexisted with operating cash flow of-$270K , indicating that accounting profit was not translating into collected cash. Accounts receivable represented96.4% of current assets, tying the reported earnings closely to customer collections rather than immediately available liquidity.
Liabilities of
Free cash flow of
Financial Health Signals
VITASPRING BIOMEDICAL CO does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
VITASPRING BIOMEDICAL CO generated $0 in revenue in Q1 2027.
Not reported for Q1 2027.
Not reported for Q1 2027.
Cash & Balance Sheet
VITASPRING BIOMEDICAL CO held $8K in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Not reported for Q1 2027.
Margins & Returns
None of these metrics is reported for Q1 2027.
Capital Allocation
None of these metrics is reported for Q1 2027.
VSBC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | $118K-49.8% | $219K-38.2% |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | -$118K+49.8% | -$219K+38.2% |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | -$115K+50.1% | -$216K+38.2% |
| Income Tax | $0-100.0% | N/A | $7K-91.3% | $12K | $11K | N/A | $78K | $0 |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | -$196K+16.5% | -$219K+38.2% |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00+100.0% | $0.00 | $0.00 |
| Diluted Shares (Avg) | 207M0.0% | N/A | 207M0.0% | 207M0.0% | 207M0.0% | N/A | 207M0.0% | 207M0.0% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Interest Expense, EPS (Basic).
VSBC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11K-4.0% | $15K+2.1% | $16K-71.8% | $17K-73.5% | $12K-90.9% | $14K-89.5% | $58K-78.9% | $64K-84.1% |
| Current Assets | $10K+3212.5% | $11K+3770.2% | $10K-76.5% | $8K-82.6% | $295-99.5% | $272-98.8% | $42K-60.7% | $45K-75.9% |
| Cash & Equivalents | $8K | $2K | $0-100.0% | $0-100.0% | $0-100.0% | $0 | $2K-21.8% | $6K-23.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.5M+10.0% | $4.4M+10.3% | $4.4M+11.1% | $4.2M+12.1% | $4.1M+12.3% | $4.0M+15.5% | $3.9M+14.1% | $3.8M+11.6% |
| Current Liabilities | $4.5M+10.0% | $4.4M+10.3% | $4.4M+11.1% | $4.2M+12.1% | $4.1M+12.3% | $4.0M+15.5% | $3.9M+14.1% | $3.8M+11.6% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$4.5M-10.0% | -$4.4M-10.3% | -$4.3M-12.3% | -$4.2M-13.6% | -$4.1M-16.2% | -$4.0M-19.8% | -$3.9M-22.3% | -$3.7M-24.6% |
| Retained Earnings | -$5.8M-7.7% | -$5.7M-207.9% | -$5.6M-9.3% | -$5.5M-10.7% | -$5.4M-13.5% | $5.3M+217.2% | -$5.1M-20.0% | -$4.9M-22.1% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
VSBC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6K+872.9% | $124+106.9% | -$839+87.0% | -$1K+51.0% | -$787+80.4% | -$2K+31.8% | -$6K-41.7% | -$2K-1387.8% |
| Depreciation & Amortization | $2K0.0% | N/A | N/A | $2K0.0% | $2K0.0% | N/A | $2K-33.9% | $2K-33.9% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | $0-100.0% | N/A | $27K-33.3% | $41K0.0% |
| Financing Cash Flow | $0-100.0% | $0 | $2K-32.8% | $2K-71.6% | $515-89.7% | $0 | $3K | $7K+74.5% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
VSBC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$4.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where VITASPRING BIOMEDICAL CO Ranks
Frequently Asked Questions
What is VITASPRING BIOMEDICAL CO's annual revenue?
VITASPRING BIOMEDICAL CO (VSBC) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is VITASPRING BIOMEDICAL CO's operating cash flow?
VITASPRING BIOMEDICAL CO (VSBC) recorded an outflow of $3K in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are VITASPRING BIOMEDICAL CO's total assets?
VITASPRING BIOMEDICAL CO (VSBC) had $15K in total assets as of fiscal year 2026, including both current and long-term assets.
What is VITASPRING BIOMEDICAL CO's current ratio?
VITASPRING BIOMEDICAL CO (VSBC) had a current ratio of 0.00 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
How does VITASPRING BIOMEDICAL CO's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, VITASPRING BIOMEDICAL CO (VSBC) held $2K in cash, cash equivalents and investments, and reported an operating cash outflow of $3K over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is VITASPRING BIOMEDICAL CO's debt-to-equity ratio negative or not reported?
VITASPRING BIOMEDICAL CO (VSBC) has negative shareholder equity of -$4.4M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.